Powel H. Brown, M.D., Ph.D. - Publications

Selected publications:

Medina D, Kittrell FS, Hill J, Shepard A, Brown P. Tamoxifen inhibition of estrogen receptor-negative mammary tumorigenesis. Submitted to Cancer Research, in press, 2005.

Kong G, Kim H-T, Wu K, DeNardo D, Hilsenbeck SG, Xu X-C, Lamph WW, Bissonnette R, Dannenberg AJ, and Brown PH. The RXR-selective retinoid, LGD1069, down-regulates COX-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Research, in press, 2005.

Denardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of ER transcription factor cross-talk in breast cancer: Identification of estrogen-induced/AP-1-dependent genes. Molecular Endocrinology, Oct 28, 2004. 19: 362-378, 2005. [PDF]

Kalidas M, Hilsenbeck S, Brown P. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst 96: 1731-1733, 2004. [PDF]

Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Research 6:240-245, 2004. [PDF]

Lui Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin dependent kinase activity. Oncogene 23:8238-46, 2004. [PDF]

Kramer R and Brown PH. Should Tamoxifen Be Used in Breast Cancer Prevention? Drug Safety, 27:979-989, 2004. [Link]

Kalidas M and Brown PH. Aromatase inhibitors for the treatment and prevention of breast cancer. Clinical Breast Cancer, In Press, 2004.

Lu, C, Mohsin S, Hilsenbeck, S., Wakeling A, Brown PH. Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. J Natl Cancer Inst 96:715-717, 2004.

Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95:1825-1833, 2003. [PDF]

Shen Q and Brown PH. Novel agents for the prevention of breast cancer: Targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8:45-73, 2003. [PDF]

Schiff R, Chamness GC and Brown PH. Advances in breast cancer treatment and prevention: Aromatase inhibitors and new SERMs. Breast Cancer Research 5:228-231, 2003. [PDF]

Wu K and Brown P. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst 95:766-767, 2003. [PDF]

Wu K, Zhang Y, Xu, X-C, Hill J, Celestino J, Kim H-T, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, and Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Research 62:6376-6380, 2002. [PDF]

Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R and Green JE. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Research 11:617-633, 2002. [PDF]

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim H-T, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, and Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21:7680-7689, 2002. [PDF]

Shah S, Pishvaian MJ, Easwaran V, Brown PH, and Byers SW. The role of cadherin β-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem 277:25313-25322, 2002. [PDF]

Wu K, Kim H-T, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu X-C, Lamph WW, Kuhn JG, Green JE, and Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD 1069. Cancer Epidemiology Biomarkers and Prevention 11:467-474, 2002. [PDF]

You H, Yu W, Munoz-Medellin-D, Brown PH, Sanders BG, and Kline K. Role of extracellular signal-regulated kinase pathway in RRR-α-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Molecular Carcinogenesis 33:228-236, 2002. [PDF]

Wu K, Liu Y, Brown P. Retinoids in breast cancer prevention. J Women’s Cancer 3:97-108, 2001.

Yang L, Ostrowski J, Reczek P and Brown P. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFβ and causing cell cycle arrest. Oncogene 20:8025-8035, 2001. [PDF]

Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D., Barr FG, Diab SG, Brown PH, Fuqua SA, and Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biological Chemistry 276:27907-12, 2001. [PDF]

Ludes-Meyers J, Liu Y, Munoz-Medellin D, Hilsenbeck S, and Brown P. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20:2771-2780, 2001. [PDF]

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Fuqua SAW, Brown P, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92:1926-34, 2000. [PDF]

Wu K, Kim H-T, Yang L-M, Tin-U C, Ludes-Myers J, Munoz-Medellin D, and Brown PH. 9-cis retinoic acid suppresses mammary tumorigenesis in C3(1)-Simian virus 40 T antigen-transgenic mice. Clinical Cancer Research 6:3696-3704, 2000. [PDF]

Brown PH and Lippman SM. Chemoprevention of breast cancer. Breast Cancer Research and Treatment 62:1-17, 2000. [PDF]

Lippman SM and Brown PH. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 91:1809-1819, 1999. [PDF]

Yang L-M, Tin-U C, Wu K, and Brown PH. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol and Neoplasia 57: 275-289, 1999. [PDF]

Smith LM, Wise SC, Hendricks DT, Sabichi AL, Brown PH, and Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18:6030-6070, 1999. [PDF]
Publications, Books/Chapters, Abstracts

Books/Chapters:

Brown P, Fuqua S and Allred C. Pathogenesis of Estrogen receptor positive and negative breast cancer. Contemporary Endocrinology: Endocrine Oncology, S. P. Ethier, ed. Humana Press Inc., Totowa, NJ, 49-68, 2000.

Sanders D, Sabichi AL, Brown PH, and Birrer MJ. Malignancies of the lung. In: The Molecular Basis of Medicine, CV Dang and AM Feldman, eds. Mosby Publishers, Chicago, IL.

Mulshine JL, Shaw GL, Cuttitta F, Scott F, Avis I, Treston AM, Linnoila RI, Birrer M, Brown P, Gupta PK, and Tockman MS. Applications of biomarkers for lung cancer early detection. In: Accomplishments in Cancer Research, J. B. Fortner, F.E. Rhoads, eds. J.B. Lippincott Co., Philadelphia, PA, 204-218, 1993.
Publications, Books/Chapters, Abstracts

Abstracts:

Wu K, Zhang Y, Celestino J, Mohsin S, Hilsenbeck S, Lamph WW, Brown PH. The RXR-selective retinoid LGD1069, prevents tumor development in MMTV-erbB2 transgenic mice. Proc Am Assoc Cancer Res 43:1007, 2002

Kim H-T, Kong G, Denardo D, Hilsenbeck S, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the RXR-selective retinoid, LGD 1069, in human breast cells using cDNA microarrays. Proc Am Assoc Cancer Res 43:824, 2002.

Kong G, Kim H-T, Denardo D, Hilsenbeck S, Lamph WW, Brown PH. RXR-selective retinoid (LGD1069) down-regulates cyclooxygenase-2 (COX-2) expression in human normal and malignant breast cells: Implications for cancer chemoprevention. Proc Am Assoc Cancer Res 43:824, 2002.

Lu C, Kim H, Liu Y, Munoz-Medellin D, Brown P. cJun-dominant-negative mutant inhibits breast cancer cell growth by inactivating critical cJun partners. Proc Am Assoc Cancer Res 43:546, 2002.

Shen Q, Liu Y, Lu C, Munoz-Medellin D, Kim H, Brown P. Mechanism by which AP-1 blockade inhibits growth and suppresses G1 cyclin expression in breast cancer cells. Breast Cancer Res Treatment 76(1):669, 2002.

Shou J, Massarweh S, Mohsin SK, Brown PH, Wakeling AE, Ali AS, Osborne K, Schiff R. Blockade of the estrogen receptor/growth factor cross-talk implicated in breast cancer tamoxifen resistance using a selective EGFR TK inhibitor. Breast Cancer Res Treatment 76(1):246, 2002.

Kim H-T, Kong G, DeNardo D, Pal S, Duong S, Hilsenbeck S, Bissonnette R, Lamph W, Johnson K, Brown P. Identification of genes regulated by the RXR-selective retinoid, LGD1069, in human breast cells using oligonucleotide arrays. Breast Cancer Res Treatment 76(1):184, 2002.

Massarweh S, Shou J, DiPietro M, Mohsin SK, Hilsenbeck SG, Wakeling AE, Brown PH, Osborne CK, Schiff R. Targeting the epidermal growth factor receptor pathway improves the anit-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. Breast Cancer Res Treatment 76(1):18, 2002.

DeNardo DG, Kim HT, Lu C, Hilsenbeck S, Brown PH. Evidence for transcription factor cross-talk in breast cancer: identification of estrogen-induced AP-1-dependent genes. Breast Cancer Res Treatment 76(1):169, 2002.

Lu C, Zhang Y, Hill J, Celestino J, Steinbis E, Bui D, Wu K, Kim H, Schiff R, Osborne K, Hilsenbeck S, Wakeling A, Brown P. Prevention of breast cancer in MMTV-ErbB2 transgenic mice using the tyrosine kinase inhibitor, ZD1839 (‘Iressa’). Breast Cancer Res Treatment 76(1):19, 2002.

Wu K, Lamph WW, Brown PH. RXR-selective retinoids function independently of RAR and PPAR? to inhibit breast cell growth. Breast Cancer Res Treatment 69(3):274, 2001.

Kim H, Munoz-Medellin D, Liu Y, Lu C, Hilsenbeck SG, Brown PH. Overexpression of cJun in breast cancer cells inhibits growth and induces cell death. Breast Cancer Res Treatment 69(3):273, 2001.

Lu C, Kim H, Liu Y, Munoz-Medellin D, Brown P. Identification of proteins associated with the AP-transcription factor that are critical for breast cancer growth. Breast Cancer Res Treatment 69(3):234, 2001.

Celestino JC, Wu K, Zhang Y, Hilsenbeck SG, Lamp W, Brown P. 9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu transgenic mice. Breast Cancer Res Treatment 69(3):226, 2001.

Lu C, Kim H-T, Lui Y, Medellin DM, and Brown PH. Identification of the dimerization partners of cJun dominant-negative mutant in breast cancer cells. Proc Am Assoc Cancer Res 42:627, 2001.

Kim H-T, Liu Y, Lu C, Munoz-Medellin D, and Brown PH. Identification of the genes regulated by AP-1 transcription factors in human breast cancer cells. Proc Am Assoc Cancer Res 42:626, 2001.

Liu Y, Zhang J, Ludes-Meyers D, Munoz-Medelin H-T, Kim G, Schiff R, Osborne CK and Brown PH. AP-1 Blocked suppresses the in vitro and in vivo growth of MCF-7 breast cancer cells. Proc Am Assoc Cancer Res 42:128, 2001.

Wu K, Tin-U CK, Hilsenbeck SG, Bischoff ED, Lamph WW and Brown PH. The RXR-selective retinoids inhibit breast cell growth by inducing a G1 cell cycle block. Proc Am Assoc Cancer Res 41:1501, 2000.

Wu K, Tin-U CK, Yang DJ, Lamph WW, Brown PH. The RXR-selective retinoid LGD1069 inhibits breast cell growth through cell cycle blockage and activation of other receptor pathways. Breast Cancer Res Treatment 64:572, 2000.

Liu Y, Ludes-Meyers J, Munoz-Medellin D, Kim H-T, and Brown PH. Breast cells require AP-1 transactivating activity for growth in response to peptide growth factors. DOD Era of Hope Breast Cancer Research Meeting, Atlanta, GA, 2000.

Kim H-T, Liu Y, Munoz-Medellin D, Brown PH. Identification of AP-1 regulated genes in human breast cancer cells. Breast Cancer Res Treatment 64:455, 2000.

Liu Y, Ludes-Meyers J, Munoz-Medellin D, Kim H-T, Zhang Y, Ge G, Schiff R, Osborne CK, Brown PH. Inhibition of AP-1 suppresses the in vitro and in vivo growth of MCF-7 breast cancer. Breast Cancer Res Treatment 64:448, 2000.

Ludes-Meyers JH, Munoz-Medellin DM, Hilsenbeck SG, Brown PH. Growth factor-induced proliferation of breast cells requires AP-1 transactivation activity. Breast Cancer Res Treatment 57:465, 1999.

Wu K, Tin-U CK, Hilsenbeck SG, Bischoff ED, Lamph WW, Blumberg B, Brown PH. The RXR-selective retinoid, LGD1069, activates RXR-and PPAR-dependent pathways in breast cells. Breast Cancer Res Treatment 57:174, 1999.

Liu Y, Ludes-Meyers J, Munoz-Medellin D, Kim H-T, Zhang Y, Ge G, Schiff R, Osborne CK, and Brown PH. Inhibition of the AP-1 transcription factor suppresses the growth of MCF-7 breast cancer cells. 7th SPORE Investigators Workshop, 1999.

Zhao H, Coronado-Heinsohn E, Seybold-Tilson K, Yang MC, Diab SG, Herrera RE, Yee D, Brown PH, Fuqua SAW, Osborne CK. Identification of FKHR as an estrogen receptor-interacting protein from tamoxifen-stimulated breast cancer. Breast Cancer Res Treatment 50:566, 1998.

Wu K, Kim H-T, Tin-U CK, Yang L-M, Hilsenbeck S, Munoz-Medellin D, Lamph W, Gottardis M, Brown PH. Receptor-selective retinoids suppress mammary tumorigenesis in C3(1)-SV40 T-antigen transgenic mice. Breast Cancer Res Treatment 50:427, 1998.

Yang L-M, Munoz-Medellin D, Ostrowski J, Reczek P, Brown PH. TGFß mediates the inhibition of normal breast cell growth by the synthetic retinoid BMS453. Breast Cancer Res Treatment 50:276, 1998.

Munoz-Medellin D, Ludes-Meyers J, Lee A, Yee D, Brown PH. Overexpression of cJun in MDA MB 435 human breast cancer cells inhibits their growth. Breast Cancer Res Treatment 50:258, 1998.

Schiff R, Ahotupa M, Reddy P, Coronado E, Hilsenbeck S, Fuqua SAW, Herrera R, Brown PH, Lawrence R, Deneke S, Osborne CK. Tamoxifen-stimulated breast tumor growth is associated with cellular oxidative stress and increased JNK activity. Breast Cancer Res Treatment 50:163, 1998.

Yang L-M, Ludes-Meyers J, Munoz-Medellin D, Wu K, Tin-U C, Ostrowski J, Reczek P, Brown PH. Mechanisms by which retinoids inhibit normal breast cell growth. 8th Annual Symposium on Cancer Research in San Antonio, p. 20, 1998.

Wu K, Kim H-T, Yang L-M, Hilsenbeck S, Tin-U CK, Muñoz-Medelin D, Lamph WW, Brown PH. 9-cis retinoic acid prevents mammary tumorigenesis in C3(1)-SV40 T-antigen transgenic mice. 8th Annual Symposium on Cancer Research in San Antonio, p. 20 (Abstr. 39), 1998.

Ludes-Meyers J, Yang L, Hilsenbeck S, Muñoz-Medellin D, Brown PH. Normal mammary epithelial cells are more dependent on AP-1 than are breast cancer cells. 8th Annual Symposium on Cancer Research in San Antonio, P. 15 (Abstr.18), 1998.

Brown PH, Wu K Tin-U C, Yang L-M, Hilsenbeck S, Green J, Lamph W, Gottardis M, Muñoz-Medellin D, Kim H-T. Suppression of breast carcinogenesis by receptor-selective retinoids. 6th SPORE Investigators' Workshop, p. 23, 1998.

Schiff R, Reddy P, Coronado E, Grim M, Herrera R, Hilsenbeck SG, Fuqua SAW, Brown PH, Osborne CK. Development of tamoxifen-stimulated growth in vivo is associated with an increase in AP-1 activity. 6th SPORE Investigators' Workshop, p. 11, 1998.

Tin-U CK, Yang L-M, Wu K, Lamph W, Gottardis M, Ludes-Meyers J, Kim H-T, Munoz-Medellin D, Brown PH. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells. Proc of the Am. Society of Clin Oncol 17:554, 1998.
Publications, Books/Chapters, Abstracts